PC(O-22:2(13Z,16Z)/22:3(10Z,13Z,16Z))

Metabolite details

Identifier

CEZAZXUWDFPTTE-FHIJIHMSSA-N

InChI Key

CEZAZXUWDFPTTE-FHIJIHMSSA-N

IUPAC name

(2-{[(2R)-2-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyloxy]-3-[(13Z,16Z)-docosa-13,16-dien-1-yloxy]propyl phosphonato]oxy}ethyl)trimethylazanium

Preferred name

PC(O-22:2(13Z,16Z)/22:3(10Z,13Z,16Z))

INN name

—

Synonym

PC(22:2n6/22:3n6)

ChEBI

CHEBI:89995

Reactome pathways

• No Reactome pathways listed for this metabolite.

Observed in studies

• Large-Scale Plasma Analysis Revealed New Mechanisms and Molecules Associated with the Host Response to SARS-CoV-2.
• Physiological extremes of the human blood metabolome: A metabolomics analysis of highly glycolytic, oxidative, and anabolic athletes
• Global analysis of plasma lipidomics reveals altered lipid signatures in patients with osteonecrosis of the femoral head
• Metabolic characterization of the natural progression of chronic hepatitis B (Lipid assays).
• Transcriptomic dynamics control rapid transition of core crop functions in 'lactating' pigeon
• Flow cytometry has a significant impact on the cellular metabolome (Lipidomic LC-MS assay)
• Dysregulation of lipid metabolism and pathological inflammation in patients with COVID-19

Observed in differential profiles

• non_COVID_19_healthy_vs_non_critical_COVID_19
• Control_Baseline_vs_Control_Post-Exercise
• Control_vs_AONFH_Stage_III_IV
• Control_vs_AONFH_Stage_III_IV
• Control_vs_Immune_Tolerant
• Control_vs_Immune_Tolerant
• Control_vs_Immune_Tolerant
• Male_19_days_vs_Male_1_day
• G1_Ctrl_vs_G2_Ab
• Mild_vs_Severe